Prevention of cardiac dysfunction during adjuvant breast cancer therapy ( PRADA): a 2 3 2 factorial, randomized, placebo-controll
![Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ... Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ...](https://pbs.twimg.com/media/E3wIBStXoAUKuLP.jpg)
Diego Segura-Rodriguez on Twitter: "📌Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (#PRADA) 🔸#Candesartan & #metoprolol during adjuvant therapy did not prevent decline in #LVEF 🔸 Not supporting broadly administered ...
![Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/7fb84603-13eb-4ad1-8525-4250c9df1d5f/gr2_lrg.jpg)
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology
![PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fbd375114c38c6feaefa42552dfdf20cb0070dd0/5-Figure1-1.png)
PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar
![Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21 Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21](https://pbs.twimg.com/media/E1gu7MIXsAE4ySO.png)
Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21
![PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol](https://congressreport.eu/storage/app/media/ACC%202021/20210525_ACC_Schuyler_Jones_INT.png)
PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol
![Geeta Gulati 1, Siri Lagethon Heck 1, Anne Hansen Ree 1, Pavel Hoffmann 2, Jeanette Schulz-Menger 3, Morten W Fagerland 2, Berit Gravdehaug 1, Florian. - ppt download Geeta Gulati 1, Siri Lagethon Heck 1, Anne Hansen Ree 1, Pavel Hoffmann 2, Jeanette Schulz-Menger 3, Morten W Fagerland 2, Berit Gravdehaug 1, Florian. - ppt download](https://images.slideplayer.com/27/8955914/slides/slide_5.jpg)
Geeta Gulati 1, Siri Lagethon Heck 1, Anne Hansen Ree 1, Pavel Hoffmann 2, Jeanette Schulz-Menger 3, Morten W Fagerland 2, Berit Gravdehaug 1, Florian. - ppt download
![Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial](https://munin.uit.no/bitstream/handle/10037/24029/article.pdf.jpg?sequence=5&isAllowed=y)
Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial
![PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fbd375114c38c6feaefa42552dfdf20cb0070dd0/4-Table2-1.png)
PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar
![Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 on Twitter: "#ACC21 #PRADA 📌 Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) 🥇best trial name 🔺RCT, Double blind 🔺 hypothesis: Long-term decline in cardiac function Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 on Twitter: "#ACC21 #PRADA 📌 Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) 🥇best trial name 🔺RCT, Double blind 🔺 hypothesis: Long-term decline in cardiac function](https://pbs.twimg.com/media/E1g3DnwXsAA7nzS.jpg)